Arkus Vol …. Issue …. 20….



**ARKUS**
Journal Homepage:

<https://hmpublisher.com/index.php/arkus>

**Title of Manuscript, 12pt, Bookman Old Style**

**Author’s name (First Name Surname)1\*, Author’s name (First Name Surname)2**

1Department of…., Faculty….., University…, City, Country

2Department of…., Faculty….., University…, City, Country

**ARTICLE INFO**

**Keywords:**

Keyword1

Keyword2

Keyword3

(Min. 3 keywords and Max. 5 keywords )

**\*Corresponding author:**

First name Surname

**E-mail address:**

***xxxx.xxxx@mail.com***

 All authors have reviewed and approved the ﬁnal version of the manuscript.

[***https://doi.org/10.37275/bsm.vxix.xx0***](https://doi.org/10.37275/bsm.vxix.xx0)

**A B S T R A C T**

The Abstract should be no more than 250 words, with 3-5 key words. It should not be descriptive, but should contain only important facts raised from the manuscript. Structured Abstract : **Background**, **Methods**, **Results**, and **Conclusion.**

1. **Introduction**

Introduction represents a short description of the problem described in the manuscript and purpose of the study. There is a need to mention only the references in the direct relationship with a problem presented in manuscript. Continue logically and finish the section with a short description of the aim of the study.1,2

1. **Methods**

Methods should present concisely and systematically a list of summarize data sources, including years searched. Include in the search the most current information possible, ideally conducting the search several months before the date of manuscript submission. Potential sources include computerized databases and published indexes, registries, abstract booklets, conference proceedings, references identified from bibliographies of pertinent articles and books, experts or research institutions active in the field, and companies or manufacturers of tests or agents being reviewed. Describe inclusion and exclusion criteria used to select studies for detailed review from among studies identified as relevant to the topic. Under details of selection include particular populations, interventions, outcomes, or methodological designs. Specify the method used to apply these criteria (for example, blinded review, consensus, multiple reviewers). State the proportion of initially identified studies that met selection criteria. Describe guidelines used for abstracting data and assessing data quality and validity (such as criteria for causal inference). State the method by which the guidelines were applied (eg, independent extraction by multiple observers).

Authors should report systematic reviews and meta-analyses in accordance with the [PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement](http://www.prisma-statement.org/).

1. **Results and discussion**

State the main results of the review, whether qualitative or quantitative, and outline the methods used to obtain these results. For meta-analyses, state the major outcomes that were pooled and include odds ratios or effect sizes and, if possible, sensitivity analyses. Accompany numerical results by confidence intervals, if applicable, and exact levels of statistical significance. For evaluations of screening and diagnostic tests, include sensitivity, specificity, likelihood ratios, receiver operating characteristic curves, and predictive values. For assessments of prognosis, summarize survival characteristics and related variables. State the major identified sources of variation between studies, including differences in treatment protocols, protocols, co-interventions, confounders, outcome measures, length of follow-up, and dropout rates.

**Tables, figures and illustrations**

Illustrations should be kept to a minimum. Data reported in tables or figures should not be repeated in the text. We accept up to five tables/figures.

Each table/figure/illustration should be presented on a separate page in the smaller format possible and contain: a) descriptive or explanatory title; b) respective number (using Arabic, not roman numerals) consecutively as cited in the text; c) all the necessary explanations of symbols and abbreviations.

**Tables.** Table title should be placed above the table.Use the MS Word table tool (table’s editor). Abbreviations may be used, but must be explained in full as footnotes. Units of measurement must be clearly indicated.

Place explanatory matter in footnotes. Explain in footnotes all abbreviations that are

used in each table. Mark the footnotes using the following symbols, in this sequence:

\*,†,‡,§,II,¶,\*\*,††,‡‡,...

**Figures**. The title should be placed below the figure. Hard copy of all **figures** (MS Excel/cdr/eps files) must be prepared and retained by authors in case it is needed during the publication process.

[**Illustrations** must be delivered in high-quality electronic format, labelled with the number and author name. To protect privacy of individuals, only body part of the interest should be presented; in the case of the need to present some pathological changes on the head, only particular detail should be presented.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

1. **Conclusion**

Conclusions should be stated in a short, clear and simple manner, stemming directly from the results shown in the paper. Rather than summarizing the data, conclude from them.

1. **References**

Each scientific fact and published statement in the text requires a relevant reference. Preferably, references should be widely visible on the Internet and refer to the most recent sources. Citing retracted and ‘predatory’ items is unacceptable.

The author is responsible for the accuracy and completeness of all references, which should be numbered sequentially and not alphabetically, with the numbers cited in the text in parenthesis, before punctuation marks according to the Vancouver style (examples following). Provide names of **all authors**. Consult *List of Journals in Index Medicus* for standard journal abbreviations.

**Journal reference**

[Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CI. Multiplexed biochemical assays with biological chips. Nature 1993; 364:555-6.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

[The Royal Marsden Hospital Bone-Marow Transplantation Team. Failure of syngeneic bone-marrow graft without preconditioning in post hepatitis marrow aplasia. Lancet 1977; 2:242-4.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

[Anonymous. Coffee drinking and cancer of the pancreas (Editorial). Br Med J 1981; 283:628.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

[Lundstrom E, Nylander C. An electrostatic approach to membranes bound receptors. Period Biol 1983; 85(Suppl 2):53-60.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

**Non English language**

Prišlin M, Pincan L, Šiftar O, Vugrovečki SA, Radin L, Vranković L, Aladrović J. Životne, prehrambene navike i stavovi studenata druge godine studija veterinarske medicine (Lifestyle, dietary habits and attitudes of second year students of veterinary medicine) [in Croaian] Veterinar 2017; 2:21-30.

***Whole book (personal authors)***

[Berry MJ, Linoff G. Data Mining Techniques for Marketing, Sales and Customer Support. New York: Wiley, 1997.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

***Whole book (editors)***

[Finch RG, Greenwood D, Norrby SR, Whitley RJ, eds. Antibiotic and Chemotherapy. 8th ed. Philadelphia: Churchill Livingston, 2003.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

***Book chapter***

[Weinstein L, Swartz MN. Pathogenic properties of invanding microorganisms. In: Sodeman WA, ed. Pathogenic Physiology: Mechanism of Disease. Philadelphia: W B Saunders, 1974:457-72.](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

***Published meeting abstract***

Uzunovic-Kamberovic S, Zorman T, Hendrickx M, Smole-Mozina S. Epidemiological relatedness among *C. jejuni* and *C. coli* PFGE genotypes from different sources. In: Abstracts of the 11th International Congress of Infectious Diseases, Cancun, Mexico, 2004. Abstract P59.003, p. 188. International Society of Infectious Diseases, Boston, MA, USA.

***Monographs***

[Hunninghake GW, Gadek JE, Szapiel SV. The human alveolar macrophage, In: Harris CC, ed. Cultured Human Cells and Tissues in Biomedical Research. New York: Academic Press, 1980: 54-6. (Stoner GD, ed. Methods and Respective in Cell Biology; Vol. 1)](http://ljkzedo.com.ba/public_html/medglasnik/Instructions%20to%20authors%20%202011.doc)

***Publication of agencies, societies***

Ranofsky AI. Surgical operations in short-stay hospitals: United States – 1975, Hyattsville, Marylend: National Centre for Health Statistics, 1978; DHEW publication no (PHS) 78-1785. (Vital and health statistics; series 13; no 34)

***Ph. D. or MA theses***

Cairins RR. Infrared spectroscopic studies of solid oxygen. Berkley, University of California, Los Angeles 1965; Ph. D. thesis.

***Website***

World Health Organization. Global strategy for the containment of antimicrobial resistance. http://www.who.International (date last accessed; an example: **07 July 2011**).

***Online reference:***

Dimick JB, Welch hg, Birkmeyer JD. Surgical mortality as an indicator of hospital quality. JAMA 292. [Online] posting or revision date. http://jama.ama-assn.org/cgi/content/short/292/7/847. (date last accessed, an example: **07 July 2011**)

References to (personal) unpublished data should be made parenthetically in the text (an example: **Brankovic, unpublished data**).